Urocidin News
Most Popular Urocidin Story
Endo licenses cancer drug for $20M up front
Endo pharmaceuticals has snagged U.S. development and marketing rights for bladder cancer drug Urocidin. The company is paying Canada's Bioniche Life Sciences up-front cash payment of $20 million and Read more...
Latest Headlines
- July 10, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
